1 5184 114 PREMATURE CHROMOSOME CONDENSATION ASSAY TO STUDY INFLUENCE OF HIGH-LEVEL NATURAL RADIATION ON THE INITIAL DNA DOUBLE STRAND BREAK REPAIR IN HUMAN G(0) LYMPHOCYTES. THE INHERENT CAPACITY OF INDIVIDUALS TO EFFICIENTLY REPAIR IONIZING RADIATION INDUCED DNA DOUBLE STRAND BREAKS (DSBS) MAY BE INHERITED, HOWEVER, IT IS INFLUENCED BY SEVERAL EPIGENETIC AND ENVIRONMENTAL FACTORS. A PILOT STUDY TESTED WHETHER CHRONIC LOW DOSE NATURAL RADIATION EXPOSURE INFLUENCES THE REJOINING OF INITIAL DNA DSBS INDUCED BY A 2 GY GAMMA-IRRADIATION IN 22 INDIVIDUALS FROM HIGH (>1.5 MGY/YEAR) AND NORMAL ( 0.05). THE VARIATION OF MTRR A66G WAS LESS SIGNIFICANTLY FREQUENT IN CASES WITH CML (68.35%) THAN IN CONTROLS (87%) (OR = 0.146, 95% CI = 0.162-0.662, P < 0.002). ADDITIONALLY, AG AND GG GENOTYPES AND G ALLELE WERE REDUCING THE CML RISK (ODDS RATIO [OR] = 0.365; 95% CI [0.179-0.746]; P = 0.006; OR = 0.292; 95% CI [0.145-0.590]; P = 0.001 AND OR = 0.146; 95% CI [0.162-0.662]; P = 0.002 AND OR = 2.0; 95% CI [1.3853-2.817]; RESPECTIVELY, (P = 0.000)). CONCLUSIONS: OUR DATA DEMONSTRATED THAT HETEROZYGOUS AND HOMOZYGOUS MUTANT GENOTYPES OF MTRR POLYMORPHISMS WERE ASSOCIATED WITH DECREASED RISK OF DEVELOPING CML IN THE SUDANESE POPULATION. 2022 9 6514 22 TRANSCRIPTIONAL ACTIVATION OF THE GP91PHOX NADPH OXIDASE SUBUNIT BY TPA IN HL-60 CELLS. THE EXPOSURE TO EPIGENETIC EFFECTORS CAPABLE OF INDUCING COPIOUS PRODUCTION OF REACTIVE OXYGEN SPECIES (ROS) HAS BEEN ASSOCIATED WITH CHRONIC INFLAMMATION, TUMOR INITIATION, AND PROMOTION. THE OBJECTIVE OF THIS STUDY WAS TO EXAMINE THE REGULATION OF GP91PHOX, THE CATALYTIC SUBUNIT OF THE NADPH OXIDASE, AND THE KINETICS OF ROS PRODUCTION IN PROMYELOCYTIC LEUKEMIA HL-60 CELLS INDUCED WITH 12-O-TETRADECONYLPHORBOL-13-ACETATE (TPA). THE TREATMENT OF HL-60 CELLS WITH TPA (0.1 MICROM) INDUCED CELLULAR DIFFERENTIATION, WHICH WAS FOLLOWED AFTER 48 H BY A TENFOLD INCREASE IN CHEMILUMINESCENCE FROM LUCIGENIN AND A 2.5-FOLD INCREASE IN THE INTRACELLULAR OXIDATION OF 2',7'-DICHOLOROFLUORESCIN (DCFH). WHEREAS HIGHER CONCENTRATIONS (1.0 MICROM) OF TPA DID NOT STIMULATE FURTHER ROS PRODUCTION, REPEATED STIMULATION WITH 0.1 MICROM TPA OF DIFFERENTIATED CELLS INDUCED A MODEST (1.2-FOLD) BUT RAPID (15 MIN) INCREASE IN CHEMILUMINESCENCE. IN CELLS TREATED WITH TPA, THE BURST IN ROS AT 48 H WAS PRECEDED BY ACCUMULATION AT 12 H OF GP91PHOX (8.8-FOLD) AND P47PHOX MRNA (THREEFOLD), WHEREAS UNTREATED CELLS CONTAINED STEADY-STATE LEVELS OF BOTH TRANSCRIPTS. TIME-COURSE EXPERIMENTS WITH ACTINOMYCIN D TO INHIBIT TRANSCRIPTION REVEALED THAT TPA DID NOT IMPROVE THE STABILITY OF GP91PHOX. IN TRANSIENT TRANSFECTIONS, LUCIFERASE REPORTER ACTIVITY DIRECTED FROM A 1.5-KB GP91PHOX PROMOTER FRAGMENT WAS ENHANCED THREEFOLD UPON TREATMENT WITH TPA FOR 24 H. WE CONCLUDE THAT TPA CAN COMMIT HL-60 CELLS TO DIFFERENTIATION AND ELICIT TRANSCRIPTION FROM THE PROXIMAL GP91PHOX PROMOTER. 2001 10 1422 21 DIFFERENTIAL CPG DNA METHYLATION OF PERIPHERAL B CELLS, CD4(+) T CELLS, AND SALIVARY GLAND TISSUES IN IGG4-RELATED DISEASE. OBJECTIVES: IMMUNOGLOBULIN-G4-RELATED DISEASE (IGG4-RD) IS A DISTINCT SYSTEMIC AUTOIMMUNE-MEDIATED DISEASE MANIFESTING AS CHRONIC INFLAMMATION AND TISSUE FIBROSIS. SINCE THE ROLE OF DNA METHYLATION IN THE PATHOGENESIS OF IGG4-RD IS STILL UNCLEAR, WE CONDUCT THIS STUDY TO INVESTIGATE EPIGENETIC MODIFICATIONS IN IGG4-RD. METHODS: A GENOME-WIDE DNA METHYLATION STUDY WAS CONDUCTED WITH B CELLS, CD4(+) T CELLS, AND SALIVARY GLAND TISSUES FROM IGG4-RD PATIENTS AND MATCHED CONTROLS BY USING THE ILLUMINA HUMANMETHYLATION 850K BEADCHIP. WE FURTHER PERFORMED PYROSEQUENCING AND IMMUNOHISTOCHEMISTRY ASSAYS TO VALIDATE THE METHYLATION STATUS OF SOME TARGETS OF INTEREST. RESULTS: WE IDENTIFIED DIFFERENTIALLY METHYLATED CPG SITES INCLUDING 44 HYPOMETHYLATED AND 166 HYPERMETHYLATED DIFFERENTIALLY METHYLATED PROBES (DMPS) IN B CELLS AND 260 HYPOMETHYLATED AND 112 HYPERMETHYLATED DMPS IN CD4(+) T CELLS FROM 10 IGG4-RD PATIENTS COMPARED WITH 10 HEALTHY CONTROLS. WE ALSO IDENTIFIED 36945 HYPOMETHYLATED AND 78380 HYPERMETHYLATED DMPS IN SALIVARY GLAND TISSUES OF 4 IGG4-RD PATIENTS COMPARED WITH 4 CONTROLS. DPM2 (CG21181453), IQCK (CG10266221), AND ABCC13 (CG05699681, CG04985582) WERE HYPERMETHYLATED AND MBP (CG18455083) WAS HYPOMETHYLATED IN B CELLS, CD4(+) T CELLS, AND SALIVARY GLAND TISSUES OF IGG4-RD PATIENTS. WE ALSO OBSERVED THE HYPOMETHYLATED HLA-DQB2 IN CD4(+) T CELLS FROM IGG4-RD PATIENTS. KYOTO ENCYCLOPEDIA OF GENES AND GENOMES (KEGG) PATHWAY ANALYSIS OF DMPS IN SALIVARY GLAND TISSUES OF IGG4-RD PATIENTS REVEALED ENRICHMENT OF PATHWAYS INVOLVED IN THE REGULATION OF IMMUNE CELL RESPONSES AND FIBROSIS. CONCLUSION: THIS IS THE FIRST DNA METHYLATION STUDY IN PERIPHERAL B CELLS, CD4(+) T CELLS, AND SALIVARY GLAND TISSUES FROM IGG4-RD PATIENTS. OUR FINDINGS HIGHLIGHTED THE ROLE OF EPIGENETIC MODIFICATION OF DNA METHYLATION AND IDENTIFIED SEVERAL GENES AND PATHWAYS POSSIBLY INVOLVED IN IGG4-RD PATHOGENESIS. 2023 11 3528 26 IL36G GENETIC VARIANT IS INDEPENDENTLY ASSOCIATED WITH SUSCEPTIBILITY, SEVERITY AND JOINT INVOLVEMENT IN PSORIASIS. PSORIASIS (PSO) IS A CHRONIC, IMMUNE-MEDIATED, INFLAMMATORY AND POLYGENIC DERMATOSIS ASSOCIATED WITH BOTH PHYSICAL AND PSYCHOLOGICAL BURDEN THAT CAN BE TRIGGERED BY INJURY, TRAUMA, INFECTIONS AND MEDICATIONS. THE ETIOLOGY OF PSO IS NOT FULLY ELUCIDATED BUT GENETIC, EPIGENETIC AND ENVIRONMENTAL FACTORS ARE ALL LIKELY TO PLAY A ROLE. A CASE-CONTROL STUDY WAS CARRIED OUT TO EVALUATE THE FREQUENCY OF THE IL36G C>T (RS13392494) AND THE IL36G A>G (RS7584409) VARIANTS AND THEIR ASSOCIATION WITH SUSCEPTIBILITY, JOINT INVOLVEMENT AND SEVERITY OF PSO. THE STUDY INCLUDED 154 PATIENTS WITH PSO AND 154 CONTROLS FROM BRAZILIAN POPULATION. THE SEVERITY OF PSO WAS ASSESSED BY THE PSORIASIS AREA AND SEVERITY INDEX (PASI). THE IL36G (RS13392494 AND RS7584409) VARIANTS WERE GENOTYPED BY ALLELIC DISCRIMINATION ASSAY USING THE REAL-TIME POLYMERASE CHAIN REACTION. THE ASSOCIATION BETWEEN THE IL36G GENETIC VARIANTS AND THE STUDY VARIABLES WAS ANALYZED IN ALLELIC, DOMINANT, CODOMINANT, OVERDOMINANT, RECESSIVE, AND HAPLOTYPE MODELS. THE MAIN RESULTS WERE THAT PSO PATIENTS WERE OLDER (P < 0.001) AND HAD HIGHER BODY MASS INDEX (P < 0.001) THAN CONTROLS; 95.8% OF THE PATIENTS HAD PLAQUE PSO, 16.1% HAD PSORIATIC ARTHRITIS (PSA), AND 27.9% HAD PASI > 10. THE IL36G RS1339294 VARIANT SHOWED NO ASSOCIATION WITH PSO IN ALL GENETIC MODELS WHILE THE IL36G RS7584409 VARIANT SHOWED A PROTECTIVE EFFECT IN PSO. HOWEVER, THE G ALLELE OF THE IL36G RS7584409 IN THE DOMINANT MODEL WAS POSITIVELY ASSOCIATED WITH PASI > 10 (P = 0.031). MOREOVER, PATIENTS WITH THE GG GENOTYPE OF THE IL36G RS7584409 VARIANT HAD ABOUT 5.0 TIMES MORE CHANCE OF PSA THAN THOSE WITH THE AA GENOTYPE (P = 0.014). REGARDING THE HAPLOTYPES, THE C/A IN A RECESSIVE MODEL (CACA VERSUS C/G AND T/A CARRIERS) WAS ASSOCIATED WITH PSO (P = 0.035) WHILE THE C/G HAPLOTYPE IN A DOMINANT MODEL (C/A CARRIERS VERSUS C/G AND T/A CARRIERS) SHOWED A PROTECTIVE EFFECT FOR PSO (P = 0.041). IN CONCLUSION, THE G ALLELE OF THE IL36G RS7584409 VARIANT WAS ASSOCIATED WITH PROTECTION TO PSO; HOWEVER, IN PATIENTS WITH PSO, THIS SAME ALLELE WAS ASSOCIATED WITH MODERATE TO SEVERE DISEASE AND PSA. THESE RESULTS SUGGEST THAT THE IL36G RS7584409 VARIANT MAY BE USED AS A POSSIBLE GENETIC BIOMARKER TO PREDICT SEVERITY AND JOINT INVOLVEMENT OF PSO. 2023 12 3305 28 HIGH-LEVEL EXPRESSION OF BCL3 DIFFERENTIATES T(2;5)(P23;Q35)-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA FROM HODGKIN DISEASE. ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) WITH T(2;5)(P23;Q35) AND HODGKIN DISEASE (HD) SHARE MANY CELLULAR FEATURES, INCLUDING EXPRESSION OF CD30. WE COMPARED GENE EXPRESSION PROFILES OF 4 ALCL (KARPAS 299, SU-DHL-1, DEL, SR-786) AND 3 HD CELL LINES AND FOUND THAT BCL3, WHICH ENCODES A NUCLEAR PROTEIN BELONGING TO THE I KAPPA B FAMILY OF INHIBITORS OF NUCLEAR FACTOR-KAPPA B (NF-KAPPA B) TRANSCRIPTIONAL FACTORS, WAS EXPRESSED AT HIGHER LEVELS IN ALCL THAN HD. NORTHERN AND WESTERN BLOTTING ANALYSES CONFIRMED THE HIGH-LEVEL EXPRESSION OF BCL3 IN ALCL AT BOTH MRNA AND PROTEIN LEVELS. WE ESTABLISHED A REAL-TIME REVERSE TRANSCRIPTASE-MEDIATED POLYMERASE CHAIN REACTION ASSAY TO MEASURE THE BCL3 MRNA LEVEL AND FOUND A PREDOMINANT LEVEL OF BCL3 EXPRESSION IN T(2;5)(+) ALCL; THE LEVELS OF CELL LINES AND CLINICAL MATERIALS WERE COMPARABLE TO OR HIGHER THAN THAT OF A B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA CARRYING T(14;19)(Q32;Q13). SOUTHERN BLOTTING AND FLUORESCENCE IN SITU HYBRIDIZATION DISCLOSED THAT THE BCL3 GENE COPIES WERE AMPLIFIED IN SU-DHL-1, WHEREAS KARPAS 299 CARRIED 4 BCL3 GENE LOCI. THE BCL3 GENE CONTAINS 2 CYTOSINE-GUANINE DINUCLEOTIDE (CPG) ISLANDS, AND THE INTRAGENIC 3' CPG WAS ENTIRELY DEMETHYLATED IN SU-DHL-1 AND DEL. IN CONTRAST TO HD, IN WHICH NF-KAPPA B WAS CONSTITUTIVELY ACTIVATED, ALCL CELLS CONSISTENTLY SHOWED (P50)(2) HOMODIMER BINDING ACTIVITY ON ELECTROPHORETIC MOBILITY SHIFT ASSAY. IT IS SUGGESTED THAT THE HIGH-LEVEL NUCLEAR BCL-3 SEQUESTERS THE (P50)(2) HOMODIMER TO THE NUCLEUS, WHICH MAY ACCOUNT FOR THE CONTRADICTORY EFFECT OF CD30 STIMULATION ON ALCL AND HD. WE PROPOSE THAT BCL3 IS OVEREXPRESSED BY GENETIC AND EPIGENETIC MODIFICATIONS, POTENTIALLY CONTRIBUTING TO THE DEVELOPMENT OF T(2;5)(+) ALCL. 2003 13 5621 25 SCREENING METHYLATION OF DNA REPAIR GENES IN THE ORAL MUCOSA OF CHRONIC SMOKERS. OBJECTIVE: THE AIM OF THIS STUDY WAS TO EVALUATE THE EPIGENETIC CHANGES IN THE PROCESS OF ORAL CARCINOGENESIS BY SCREENING THE METHYLATION OF REPAIR GENES IN CHRONIC SMOKERS. DESIGN: TWO GROUPS WERE FORMED: GROUP 1: 16 SMOKERS WITH CONSUMPTION OF 20 CIGARETTES/DAY FOR AT LEAST 10 YEARS; AND GROUP 2: 10 NON-SMOKING. EXFOLIATIVE CYTOLOGY OF THE TONGUE WAS PERFORMED, AND THE EXTRACTED DNA WAS TREATED BY ENZYMES. THE PCR ARRAY SYSTEM PERFORMED METHYLATION SCREENING TO EVALUATE 22 DNA REPAIR GENES, AND THE RESULTS WERE VALIDATED BY RT-QPCR FOR EACH GENE WITH METHYLATION LEVELS >/=10%. RESULTS: HIGHEST PERCENTAGES OF METHYLATION WERE OBSERVED FOR MLH3 AND XRCC1 GENES (11-20% METHYLATION) AND IN ONE CASE FOR MRE11A AND PMS2 (>50% METHYLATION). STATISTICAL ANALYSIS SHOWED SIGNIFICANT DIFFERENCES IN THE EXPRESSION OF THE GENES MRE11A (P = 0.0002), PMS2(P = 0.0068), XRCC1 (P = 0.0080) AND MLH3 (0.0057) BETWEEN THE TWO GROUPS. CONCLUSION: THE EFFECTS OF CHRONIC SMOKING ON ORAL MUCOSA LED TO THE METHYLATION OF GENES MRE11A PMS2, XRCC1 AND MLH3, BUT RESULTED IN A REDUCTION OF GENE EXPRESSION OF MRE11A AND PMS2, WHICH SHOWED >/=50% METHYLATION. THESE RESULTS PROVIDE EVIDENCE THAT SMOKING CAUSE METHYLATION AND REDUCED EXPRESSION OF REPAIR GENES. 2018 14 6593 22 TUMOR-ASSOCIATED MACROPHAGES PROMOTE EPIGENETIC SILENCING OF GELSOLIN THROUGH DNA METHYLTRANSFERASE 1 IN GASTRIC CANCER CELLS. EPIGENETIC REPRESSION OF THE TUMOR SUPPRESSOR GELSOLIN (GSN) IS FREQUENTLY OBSERVED IN CANCERS. CHRONIC INFLAMMATION CAN PROMOTE TUMOR PROGRESSION VIA ABERRANT DNA METHYLATION. IN THIS STUDY, WE INVESTIGATED THE ROLE OF TUMOR-ASSOCIATED MACROPHAGES (TAMS) IN DNA METHYLATION OF THE GSN GENE DURING GASTRIC CANCER PROGRESSION. IMMUNOFLUORESCENCE STAINING OF 121 GASTRIC CANCER TISSUES SHOWED ABERRANT LOCALIZATION OF GSN AND DNA METHYLTRANSFERASE 1 (DNMT1) AND JUXTAPOSITION OF DNMT1 AND M2 TAMS. DECREASED GSN PROTEIN AND MRNA EXPRESSION AND INCREASED DNA METHYLATION IN THE GSN PROMOTER WERE OBSERVED IN GASTRIC CANCER CELL LINES AND CLINICAL SPECIMENS. TO EXAMINE THE EFFECT OF TAMS ON DNA METHYLATION IN GASTRIC CANCER CELLS, WE PERFORMED IN VITRO COCULTURE ASSAYS AND FOUND INCREASED DNMT1 EXPRESSION BUT DECREASED GSN EXPRESSION IN GASTRIC CANCER CELLS AFTER COCULTURE WITH U937 CELLS. KNOCKDOWN OF DNMT1 EXPRESSION IN GASTRIC CANCER CELLS COULD ABORT U937 COCULTURE-MEDIATED GSN DOWNREGULATION. MEANWHILE, CCL5 WAS THE MAIN CHEMOKINE UPREGULATED IN COCULTURE MEDIUM. TREATMENT WITH CCL5 COULD INDUCE DNMT1 EXPRESSION IN GASTRIC CANCER CELLS VIA STAT3 SIGNALING. INHIBITING DNMT1 ACTIVITY WITH PROCAINAMIDE, INHIBITING DNA METHYLATION WITH 5-AZA, OR INHIBITING CCL5/CCR5 SIGNALING WITH MARAVIROC REDUCED TUMOR GROWTH IN VIVO IN CONCLUSION, UPREGULATION OF DNMT1 BY CCL5/CCR5/STAT3 SIGNALING IS CRITICAL FOR TAM-MEDIATED GSN SILENCING IN GASTRIC CANCER. THIS STUDY IDENTIFIED POTENTIAL TARGETS FOR GASTRIC CANCER THERAPY. CANCER IMMUNOL RES; 5(10); 885-97. (C)2017 AACR. 2017 15 6634 19 UNINTEGRATED TWO-LONG TERMINAL REPEAT CIRCULAR HUMAN T LYMPHOTROPIC VIRUS DNA ACCUMULATION DURING CHRONIC HTLV INFECTION. ACCUMULATION OF UNINTEGRATED HUMAN T LYMPHOTROPIC VIRUS (HTLV) DNA WAS ANALYZED IN LONG-TERM T CELL LINES INFECTED WITH HTLV TYPE I (HTLV-I) OR TYPE II (HTLV-II). BY USING A POLYMERASE CHAIN REACTION-BASED ASSAY, AMPLIFIED PRODUCTS OF EXPECTED SIZE WERE OBTAINED IN ALL OF THE HTLV-I-INFECTED (N = 7) AND HTLV-II-INFECTED (N = 8) CELL LINES. THE SIGNAL INTENSITIES OF THE HYBRIDIZING BAND VARIED GREATLY AMONG THE CELL LINES AND DID NOT CORRELATE WITH HTLV P24GAG ANTIGEN PRODUCTION. FURTHER ANALYSIS OF HTLV-I-INFECTED CLONES DEMONSTRATED CONSIDERABLE VARIABILITY IN THE UNINTEGRATED DNA ACCUMULATION, SUGGESTING THAT EITHER THE EPIGENETIC STATUS OF THE HOST CELL OR SOME ENVIRONMENTAL FACTOR DETERMINES THE OCCURRENCE OF UNINTEGRATED DNA. THE PRESENCE OF LOWER LEVELS OF UNINTEGRATED DNA IN MOST OF THE HTLV-INFECTED, LONG-TERM CELL LINES PRESUMABLY RESULTS IN PERSISTENT NONCYTOPATHIC INFECTION. 1993 16 1286 22 DECITABINE IN COMBINATION WITH DONOR LYMPHOCYTE INFUSIONS CAN INDUCE REMISSIONS IN RELAPSED MYELOID MALIGNANCIES WITH HIGHER LEUKEMIC BURDEN AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION. THE COMBINATION OF 5-AZACYTIDINE (AZA) WITH DONOR LYMPHOCYTE INFUSIONS (DLIS) CAN INDUCE REMISSIONS IN PATIENTS WITH RELAPSED MYELOID MALIGNANCIES AFTER ALLO-HCT. AS DECITABINE (DAC) IS KNOWN TO BE EFFECTIVE ALSO IN AML/MDS WITH LEUKOCYTOSIS, WE INVESTIGATED THE COMBINATION OF DAC WITH DLIS FOR RELAPSE AFTER ALLO-HCT. BETWEEN 2006 AND 2016, 26 PATIENTS (MEDIAN AGE 59 YEARS) WITH AML (N = 18), MDS (N = 6), OR MPN (N = 2) AND OVERT HEMATOLOGICAL RELAPSE AFTER ALLO-HCT WERE TREATED. MEDIAN DURATION FROM ALLO-HCT TO RELAPSE WAS 306 DAYS (RANGE, 76-4943). EIGHTEEN PATIENTS RECEIVED DAC + DLIS, 8 DAC-ONLY (MEDIAN NUMBER CYCLES OF DAC: 2, RANGE 1-13, MEDIAN NUMBER OF DLIS: 2, RANGE 1-10). THE INCIDENCE OF ACUTE AND CHRONIC GVHD IN PATIENTS RECEIVING DLI WAS 17% (3/18) AND 6% (1/18), RESPECTIVELY. CR/CRI WAS ACHIEVED IN 15% (4/26), PR IN 4% (1/26), AND STABLE DISEASE IN 58% (15/26) OF PATIENTS. EIGHT PATIENTS RECEIVED A SECOND ALLO-HCT. MEDIAN OVERALL SURVIVAL WAS 4.7 MONTHS. ELEVATED PD-L1 PROTEIN EXPRESSION IN BONE MARROW CELLS WAS DETECTED IN 4/8 PATIENTS WITH >20% BLAST INFILTRATION PRIOR TO DAC, WITHOUT A CLEAR ASSOCIATION WITH RESPONSE. IN CONCLUSION, THE DAC + DLI REGIMEN PROVED FEASIBLE AND EFFECTIVE IN RELAPSED MYELOID MALIGNANCIES AFTER ALLO-HCT, WITH EFFICACY NOT RESTRICTED TO PATIENTS WITH LOW LEUKEMIC BURDEN. 2018 17 1950 27 EPIGENETIC ACTIVATION OF TENSIN 4 PROMOTES GASTRIC CANCER PROGRESSION. GASTRIC CANCER (GC) IS A COMPLEX DISEASE INFLUENCED BY MULTIPLE GENETIC AND EPIGENETIC FACTORS. CHRONIC INFLAMMATION CAUSED BY HELICOBACTER PYLORI INFECTION AND DIETARY RISK FACTORS CAN RESULT IN THE ACCUMULATION OF ABERRANT DNA METHYLATION IN GASTRIC MUCOSA, WHICH PROMOTES GC DEVELOPMENT. TENSIN 4 (TNS4), A MEMBER OF THE TENSIN FAMILY OF PROTEINS, IS LOCALIZED TO FOCAL ADHESION SITES, WHICH CONNECT THE EXTRACELLULAR MATRIX AND CYTOSKELETAL NETWORK. WE IDENTIFIED UPREGULATION OF TNS4 IN GC USING QUANTITATIVE REVERSE TRANSCRIPTION PCR WITH 174 PAIRED SAMPLES OF GC TUMORS AND ADJACENT NORMAL TISSUES. TRANSCRIPTIONAL ACTIVATION OF TNS4 OCCURRED EVEN DURING THE EARLY STAGE OF TUMOR DEVELOPMENT. TNS4 DEPLETION IN GC CELL LINES THAT EXPRESSED HIGH TO MODERATE LEVELS OF TNS4, I.E., SNU-601, KATO III, AND MKN74, REDUCED CELL PROLIFERATION AND MIGRATION, WHEREAS ECTOPIC EXPRESSION OF TNS4 IN THOSE LINES THAT EXPRESSED LOWER LEVELS OF TNS4, I.E., SNU-638, MKN1, AND MKN45 INCREASED COLONY FORMATION AND CELL MIGRATION. THE PROMOTER REGION OF TNS4 WAS HYPOMETHYLATED IN GC CELL LINES THAT SHOWED UPREGULATION OF TNS4. WE ALSO FOUND A SIGNIFICANT NEGATIVE CORRELATION BETWEEN TNS4 EXPRESSION AND CPG METHYLATION IN 250 GC TUMORS BASED ON THE CANCER GENOME ATLAS (TCGA) DATA. THIS STUDY ELUCIDATES THE EPIGENETIC MECHANISM OF TNS4 ACTIVATION AND FUNCTIONAL ROLES OF TNS4 IN GC DEVELOPMENT AND PROGRESSION AND SUGGESTS A POSSIBLE APPROACH FOR FUTURE GC TREATMENTS. 2023 18 2125 26 EPIGENETIC INACTIVATION OF DLX4 IS ASSOCIATED WITH DISEASE PROGRESSION IN CHRONIC MYELOID LEUKEMIA. ABERRANT DNA METHYLATION OF VARIOUS GENES HAS BEEN IDENTIFIED TO BE ASSOCIATED WITH DISEASE PROGRESSION IN CHRONIC MYELOID LEUKEMIA (CML). OUR STUDY WAS INTENDED TO INVESTIGATE DLX4 METHYLATION PATTERN IN DIFFERENT CLINICAL STAGES OF CML AND FURTHER DETERMINE ITS ROLE IN REGULATING DLX4 EXPRESSION. REAL-TIME QUANTITATIVE METHYLATION-SPECIFIC PCR AND BISULFITE SEQUENCING PCR WERE APPLIED TO DETECT DLX4 METHYLATION. 5-AZA-2'-DEOXYCYTIDINE (5-AZA-DC) WAS USED FOR DEMETHYLATION STUDIES. DLX4 WAS SIGNIFICANTLY HYPERMETHYLATED IN CML PATIENTS (P = 0.002) ESPECIALLY IN BLASTIC PHASE (BC) STAGE (P < 0.001) AS COMPARED WITH CONTROLS. MOREOVER, DLX4 METHYLATION LEVEL IN BC STAGE WAS SIGNIFICANTLY HIGHER THAN IN CHRONIC PHASE (CP) STAGE (P < 0.001). DLX4 METHYLATION DENSITY WAS SIGNIFICANTLY INCREASED DURING THE PROGRESSION OF CML AMONG THE TESTED TWO PATIENTS (P < 0.001). DLX4 HYPERMETHYLATION OCCURRED WITH THE HIGHEST INCIDENCE IN BC STAGE (83%), LOWER INCIDENCE IN ACUTE PHASE (AP) STAGE (43%), AND THE LOWEST INCIDENCE IN CP STAGE (26%) (P = 0.001). MOREOVER, T(9; 22) WITH ADDITIONAL ALTERATION CASES HAD SIGNIFICANTLY HIGHER FREQUENCY OF DLX4 HYPERMETHYLATION COMPARED WITH THE OTHER CYTOGENETICS (P = 0.010). SIGNIFICANTLY NEGATIVE CORRELATION WAS OBSERVED BETWEEN DLX4 METHYLATION AND DLX4-TV2 (THE SHORTER DLX4 ISOFORM) EXPRESSION (R = -0.382, P = 0.001, N = 78) BUT NOT BETWEEN DLX4 METHYLATION AND BP1 (THE LONGER DLX4 ISOFORM) EXPRESSION (R = 0.134, P = 0.244, N = 78) IN CML PATIENTS. BOTH DLX4-TV2 AND BP1 MRNA WERE SIGNIFICANTLY INCREASED AFTER 5-AZA-DC TREATMENT IN K562 CELL LINE (P < 0.001). OUR STUDY INDICATED THAT HYPERMETHYLATION OF DLX4 CORRELATED WITH DISEASE PROGRESSION OF CML. MOREOVER, DLX4 EXPRESSION WAS REGULATED BY ITS METHYLATION IN CML. 2015 19 5017 20 PERSISTENT INFECTION OF CULTURED CELLS WITH MOUSE HEPATITIS VIRUS (MHV) RESULTS FROM THE EPIGENETIC EXPRESSION OF THE MHV RECEPTOR. THE A59 STRAIN OF MURINE CORONAVIRUS MOUSE HEPATITIS VIRUS (MHV) CAN CAUSE PERSISTENT INFECTION OF 17C1-1 CELLS AND OTHER MURINE CELL LINES. PERSISTENTLY INFECTED CULTURES RELEASED LARGE AMOUNTS OF VIRUS (10(7) TO 10(8) PFU/ML) AND WERE RESISTANT TO SUPERINFECTION WITH MHV BUT NOT TO INFECTION WITH UNRELATED SEMLIKI FOREST AND VESICULAR STOMATITIS VIRUSES. THE CULTURE MEDIUM FROM PERSISTENTLY INFECTED CULTURES DID NOT CONTAIN A SOLUBLE INHIBITOR SUCH AS INTERFERON THAT PROTECTED UNINFECTED CELLS FROM INFECTION BY MHV OR VESICULAR STOMATITIS VIRUS. THE PERSISTENT INFECTION WAS CURED IF FEWER THAN 100 CELLS WERE TRANSFERRED DURING SUBCULTURING, AND SUCH CURED CULTURES WERE SUSCEPTIBLE TO REINFECTION AND THE REESTABLISHMENT OF PERSISTENT INFECTION. CULTURES OF 17C1-1 CELLS THAT HAD BEEN NEWLY CLONED FROM SINGLE CELLS CONSISTED OF A MIXTURE OF MHV-RESISTANT AND -SUSCEPTIBLE CELLS. 17C1-1/#97 CELLS, WHICH WERE CURED BY SUBCLONING AFTER 97 PASSAGES OF A PERSISTENTLY INFECTED CULTURE OVER A 1-YEAR PERIOD, CONTAINED 5 TO 10% OF THEIR POPULATION AS SUSCEPTIBLE CELLS, WHILE 17C1-1/#402 CELLS, WHICH WERE CURED BY SUBCLONING AFTER 402 PASSAGES OVER A 3-YEAR PERIOD, HAD LESS THAN 1% SUSCEPTIBLE CELLS. SUSCEPTIBILITY TO INFECTION CORRELATED WITH THE EXPRESSION OF MHV RECEPTOR GLYCOPROTEIN (MHVR [BGP1A]). FLUORESCENCE-ACTIVATED CELL SORTER ANALYSIS WITH ANTIBODY TO MHVR SHOWED THAT 17C1-1/#97 CELLS CONTAINED A SMALL FRACTION OF MHVR-EXPRESSING CELLS. THESE MHVR-EXPRESSING CELLS WERE SELECTIVELY ELIMINATED WITHIN 24 H AFTER CHALLENGE WITH MHV-A59, AND PRETREATMENT OF 17C1-1/#97 CELLS WITH MONOCLONAL ANTIBODY CC1, WHICH BINDS TO THE N-TERMINAL DOMAIN OF MHVR, BLOCKED INFECTION. WE CONCLUDE THAT THE SUBPOPULATION OF MHVR-EXPRESSING CELLS WERE INFECTED AND KILLED IN ACUTELY OR PERSISTENTLY INFECTED CULTURES, WHILE THE SUBPOPULATION OF MHVR-NONEXPRESSING CELLS SURVIVED AND PROLIFERATED. THE SUBPOPULATION OF MHVR-NEGATIVE CELLS PRODUCED A SMALL PROPORTION OF PROGENY CELLS THAT EXPRESSED MHVR AND BECAME INFECTED, THEREBY MAINTAINING THE PERSISTENT INFECTION AS A STEADY-STATE CARRIER CULTURE. THUS, IN 17C1-1 CELL CULTURES, THE UNSTABLE OR EPIGENETIC EXPRESSION OF MHVR PERMITTED THE ESTABLISHMENT OF A PERSISTENT, CHRONIC INFECTION. 1995 20 3805 25 INTESTINE-SPECIFIC HOMEOBOX (ISX) INDUCES INTESTINAL METAPLASIA AND CELL PROLIFERATION TO CONTRIBUTE TO GASTRIC CARCINOGENESIS. BACKGROUND: HELICOBACTER PYLORI INDUCES CHRONIC INFLAMMATION AND INTESTINAL METAPLASIA (IM) THROUGH GENETIC AND EPIGENETIC CHANGES AND ACTIVATION OF INTRACELLULAR SIGNALING PATHWAYS THAT CONTRIBUTE TO GASTRIC CARCINOGENESIS. HOWEVER, THE PRECISE MECHANISM OF IM IN GASTRIC CARCINOGENESIS HAS NOT BEEN FULLY ELUCIDATED. WE PREVIOUSLY FOUND THAT INTESTINE-SPECIFIC HOMEOBOX (ISX) MRNA EXPRESSION INCREASED IN ORGANOIDS CULTURED FROM HELICOBACTER-INFECTED MOUSE MUCOSA. IN THIS STUDY, WE ELUCIDATE THE ROLE OF ISX IN THE DEVELOPMENT OF IM AND GASTRIC CARCINOGENESIS. METHODS: ISX EXPRESSION WAS ASSESSED IN HELICOBACTER-INFECTED MOUSE AND HUMAN GASTRIC MUCOSA. MKN45 GASTRIC CANCER CELLS WERE CO-CULTURED WITH H. PYLORI TO DETERMINE WHETHER HELICOBACTER INFECTION INDUCED ISX EXPRESSION. WE ESTABLISHED STABLE MKN45 TRANSFECTED CELLS EXPRESSING ISX (STABLE-ISX MKN45) AND PERFORMED A SPHEROID COLONY FORMATION ASSAY AND A XENOGRAFT MODEL. WE PERFORMED ISX IMMUNOHISTOCHEMISTRY IN CANCER AND ADJACENT GASTRIC TISSUES. RESULTS: ISX EXPRESSION WAS INCREASED IN MOUSE AND HUMAN GASTRIC MUCOSA INFECTED WITH HELICOBACTER. THE PRESENCE OF IM AND H. PYLORI INFECTION IN HUMAN STOMACH WAS CORRELATED WITH ISX EXPRESSION. H. PYLORI INDUCED ISX MRNA AND PROTEIN EXPRESSION. CDX1/2, CYCLIND1, AND MUC2 WERE UPREGULATED IN STABLE-ISX MKN45, WHEREAS MUC5AC WAS DOWNREGULATED. STABLE-ISX MKN45 CELLS FORMED MORE SPHEROID COLONIES, AND HAD HIGH TUMORIGENIC ABILITY. ISX EXPRESSION IN GASTRIC CANCER AND ADJACENT MUCOSA WERE CORRELATED. CONCLUSIONS: ISX EXPRESSION INDUCED BY H. PYLORI INFECTION MAY LEAD TO IM AND HYPERPROLIFERATION OF GASTRIC MUCOSA THROUGH CDX1/2 AND CYCLIND1 EXPRESSION, CONTRIBUTING TO GASTRIC CARCINOGENESIS. 2016